Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

McGuirk

Showing results (521-530 of 583) with videos related to

Pageof 59
Sort By:
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
JAMA Oncology|April 21, 2022
Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell TransplantQamar J Khan, Cory R Bivona, Grace A Martin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 12, 2017
Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic LeukemiaBetty Ky Hamilton, Lisa Rybicki, Donna Abounader, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Oncogene|February 3, 2022
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotinMarco Biondini, Alex Kiepas, Leeanna El-Houjeiri, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood|July 22, 2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Rizwan Romee, Andrew St Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
Blood Advances|September 8, 2021
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndromeAlex F Herrera, Kwang Woo Ahn, Carlos Litovich, et al.
Eclinicalmedicine|May 2, 2023
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational studyJoshua A Hill, Michael J Martens, Jo-Anne H Young, et al.
Pageof 59

Showing results (521-530 of 583) with videos related to

Sort By:
Pageof 59
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
JAMA Oncology|April 21, 2022
Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell TransplantQamar J Khan, Cory R Bivona, Grace A Martin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 12, 2017
Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic LeukemiaBetty Ky Hamilton, Lisa Rybicki, Donna Abounader, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Oncogene|February 3, 2022
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotinMarco Biondini, Alex Kiepas, Leeanna El-Houjeiri, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood|July 22, 2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Rizwan Romee, Andrew St Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
Blood Advances|September 8, 2021
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndromeAlex F Herrera, Kwang Woo Ahn, Carlos Litovich, et al.
Eclinicalmedicine|May 2, 2023
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational studyJoshua A Hill, Michael J Martens, Jo-Anne H Young, et al.
Pageof 59